Clinical Trials Search
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors
The purpose of this study is to test the safety of MK-3475 along with ziv-aflibercept, given by vein, at different doses to find out what effects, if any, it has on participants.
To determine the safety, tolerability and recommended phase II dosing for the combination of ziv-aflibercept plus MK-3475 in patients with unresectable stage III or stage IV melanoma, renal cell cancer, ovarian cancer, or colorectal cancer.
MK-3475 (Keytruda); Ziv-aflibercept ()